生物基因BIIB
那斯達克 · USD
211.81
-0.69
(-0.32%)
盤中 09/10 01:12 (UTC+8)
09/10 01:12 (UTC+8)
生物基因BIIB
211.81
-0.69
(-0.32%)
財務數據
損益表
- 22.91
- 24.65
- 24.66
- 24.55
- 24.31
- 26.46
- 25.35
- 22.79
- 24.78
- 27.36
- -4.01
- 7.61
- 0.04
- -0.45
- -0.97
- 8.82
- -4.19
- -10.07
- 8.70
- 10.42
- 營業收入(億)
- 季增長率(%)
單位：美元千元
2026/Q2 | 2026/Q1 | 2025/Q4 | 2025/Q3 | 2025/Q2 | 2025/Q1 | 2024/Q4 | 2024/Q3 | 2024/Q2 | 2024/Q1 | |
營業收入淨額 | 2,736,000 | 2,477,800 | 2,279,400 | 2,534,700 | 2,645,500 | 2,431,000 | 2,454,700 | 2,465,800 | 2,464,900 | 2,290,500 |
營業成本 | 776,900 | 661,000 | 495,500 | 674,400 | 605,000 | 629,300 | 583,500 | 638,700 | 546,000 | 542,200 |
營業毛利 | 1,959,100 | 1,816,800 | 1,783,900 | 1,860,300 | 2,040,500 | 1,801,700 | 1,871,200 | 1,827,100 | 1,918,900 | 1,748,300 |
營業費用 | 1,808,200 | 1,419,400 | 1,685,500 | 1,268,900 | 1,247,800 | - | 1,429,800 | - | - | - |
研發費用 | 529,600 | 539,000 | 509,400 | 436,100 | 399,000 | 434,100 | 574,800 | 542,700 | 521,400 | 452,900 |
推銷及管理費用 | 781,000 | 702,000 | 757,600 | 687,600 | 672,000 | 640,200 | 741,000 | 681,500 | 616,200 | 647,100 |
非經常性項目費用 | 329,400 | 41,900 | 281,900 | 9,500 | 45,900 | 236,000 | -37,200 | 6,800 | -900 | 11,500 |
其他營業費用 | 168,200 | 136,500 | 136,600 | 135,700 | 130,900 | 111,800 | 151,200 | 130,300 | 86,900 | 78,300 |
營業利益 | 150,900 | 397,400 | 98,400 | 591,400 | 792,700 | 379,600 | 441,400 | 465,800 | 695,300 | 558,500 |
其他收入及費用 | -18,500 | -19,700 | -154,400 | -34,100 | -48,700 | -68,400 | -149,900 | -14,800 | 3,400 | -93,700 |
利息費用 | - | - | - | - | - | - | - | - | - | - |
稅前純益 | 132,400 | 377,700 | -56,000 | 557,300 | 744,000 | 311,200 | 291,500 | 451,000 | 698,700 | 464,800 |
所得稅 | 34,900 | 58,200 | -7,100 | 90,800 | 109,200 | 70,700 | 24,800 | 62,500 | 115,100 | 71,400 |
稅後純益 | 97,500 | 319,500 | -48,900 | 466,500 | 634,800 | 240,500 | 266,700 | 388,500 | 583,600 | 393,400 |
基本每股稅後盈餘(元) | 0.66 | 2.17 | -0.33 | 3.18 | 4.33 | 1.65 | 1.83 | 2.67 | 4.01 | 2.71 |
稀釋每股稅後盈餘(元) | 0.66 | 2.15 | -0.35 | 3.17 | 4.33 | 1.64 | 1.83 | 2.65 | 4.00 | 2.70 |
基本平均股數(千股) | 147700.00 | 147200.00 | 146700.00 | 146600.00 | 146500.00 | 146100.00 | 145700.00 | 145700.00 | 145600.00 | 145200.00 |
稀釋平均股數(千股) | 148700.00 | 148400.00 | 146700.00 | 147100.00 | 146700.00 | 146600.00 | 146100.00 | 146100.00 | 145900.00 | 145900.00 |
還原基本每股稅後盈餘(元) | 0.66 | 2.17 | -0.33 | 3.18 | 4.33 | 1.65 | 1.83 | 2.67 | 4.01 | 2.71 |
還原稀釋每股稅後盈餘(元) | 0.66 | 2.15 | -0.35 | 3.17 | 4.33 | 1.64 | 1.83 | 2.65 | 4.00 | 2.70 |
還原基本平均股數(千股) | 147,700 | 147,200 | 146,700 | 146,600 | 146,500 | 146,100 | 145,700 | 145,700 | 145,600 | 145,200 |
還原稀釋平均股數(千股) | 148,700 | 148,400 | 146,700 | 147,100 | 146,700 | 146,600 | 146,100 | 146,100 | 145,900 | 145,900 |
EBITDA(千元) | 571,300 | 689,700 | 219,600 | 821,000 | 990,800 | 545,800 | 520,400 | 684,700 | 947,700 | 656,400 |